"Glucosylceramidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycosidase that hydrolyzes a glucosylceramide to yield free ceramide plus glucose. Deficiency of this enzyme leads to abnormally high concentrations of glucosylceramide in the brain in GAUCHER DISEASE. EC 3.2.1.45.
| Descriptor ID |
D005962
|
| MeSH Number(s) |
D08.811.277.450.420.412
|
| Concept/Terms |
Glucosylceramidase- Glucosylceramidase
- beta-Glucocerebrosidase
- beta Glucocerebrosidase
- Acid beta-Glucosidase
- Acid beta Glucosidase
- beta-Glucosidase, Acid
- Glucocerebroside beta-Glucosidase
- Glucocerebroside beta Glucosidase
- beta-Glucosidase, Glucocerebroside
- Glucosylceramide beta-Glucosidase
- Glucosylceramide beta Glucosidase
- beta-Glucosidase, Glucosylceramide
- Glucosylsphingosine Glucosyl Hydrolase
- Glucosyl Hydrolase, Glucosylsphingosine
- Hydrolase, Glucosylsphingosine Glucosyl
- Glucosyl Ceramidase
- Ceramidase, Glucosyl
- Glucocerebrosidase
|
Below are MeSH descriptors whose meaning is more general than "Glucosylceramidase".
Below are MeSH descriptors whose meaning is more specific than "Glucosylceramidase".
This graph shows the total number of publications written about "Glucosylceramidase" by people in this website by year, and whether "Glucosylceramidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 6 | 1 | 7 |
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 0 | 3 |
| 2013 | 4 | 0 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucosylceramidase" by people in Profiles.
-
PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases. Proc Natl Acad Sci U S A. 2023 01 03; 120(1):e2210442120.
-
Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease. Cells. 2021 09 02; 10(9).
-
Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. EBioMedicine. 2020 May; 55:102735.
-
Intravenous infusion of iPSC-derived neural precursor cells increases acid ?-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease. Hum Mol Genet. 2019 10 15; 28(20):3406-3421.
-
Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease. Neurobiol Dis. 2019 10; 130:104513.
-
Combination of acid ?-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype. Sci Rep. 2019 04 03; 9(1):5571.
-
Small Bowel Mucosal Involvement and Mesenteric Mass Formation in a Young Female with Type 3 Gaucher Disease. A Case Report. J Gastrointestin Liver Dis. 2018 Dec; 27(4):459-463.
-
An unexpected player in Gaucher disease: The multiple roles of complement in disease development. Semin Immunol. 2018 06; 37:30-42.
-
Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa. J Am Acad Dermatol. 2017 Aug; 77(2):268-273.e6.
-
Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017 03 02; 543(7643):108-112.